Homocysteine reduces protein S-nitrosylation in endothelium

Yulong Chen1, Sihai Zhao2, Yanli Wang2

  • 1Research Institute of Atherosclerotic Disease, Xi'an Jiaotong University Cardiovascular Research Center, Xi'an, Shaanxi 710061, P.R. China.

Insights

High homocysteine (HHcy) impairs cardiovascular health by reducing protein S-nitrosylation in endothelial cells. This leads to increased oxidative stress and impaired nitric oxide production, contributing to vascular dysfunction.

Area of Science:

  • Cardiovascular Biology
  • Endothelial Function
  • Molecular Medicine

Background:

  • Hyperhomocysteinemia (HHcy) is a known risk factor for cardiovascular disease.
  • Protein S-nitrosylation regulates critical cardiovascular functions.
  • The specific mechanism by which homocysteine (Hcy) affects endothelial S-nitrosylation remains unclear.

Purpose of the Study:

  • To investigate whether Hcy impairs vascular endothelial functions by inhibiting protein S-nitrosylation.
  • To elucidate the molecular pathways involved in Hcy-induced endothelial dysfunction.

Main Methods:

  • Experiments conducted in human umbilical vein endothelial cells (HUVECs) and in vivo Sprague-Dawley rats.
  • Assessed S-nitrosylation using immunofluorescence and biotin switch method.
  • Measured reactive oxygen species (ROS), nitric oxide (NO) levels, protein expression (Western blot), NF-κB activity (EMSA), and plasma Hcy (ELISA).

Main Results:

  • Hcy significantly reduced protein S-nitrosylation in HUVECs and rat aorta endothelium.
  • This reduction correlated with increased ROS, decreased Akt/eNOS phosphorylation, and lower NO levels.
  • Hcy elevated vascular cell adhesion molecule-1 expression by attenuating NF-κB (p65) S-nitrosylation.

Conclusions:

  • Hcy impairs endothelial cell function primarily by inhibiting endothelial protein S-nitrosylation.
  • This inhibition contributes to oxidative stress, reduced NO bioavailability, and inflammation.
  • Targeting S-nitrosylation pathways may offer therapeutic strategies for HHcy-related cardiovascular disease.

Related Concept Videos

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
750
Nitric Oxide Signaling Pathway01:28

Nitric Oxide Signaling Pathway

Nitric oxide (NO), an inorganic gas, acts as a potent second messenger in most animal and plant tissues. NO diffuses out of the cells that produce it and enters the neighboring cells to generate a downstream response. NO synthase (NOS) catalyzes NO production by the deamination of the amino acid arginine. There are three isoforms of NOS. Endothelial cells have endothelial NOS (eNOS), nerve and muscle cells have neuronal NOS (nNOS), and macrophages produce inducible NOS (iNOS) upon exposure...
5.2K
Sulfur Assimilation01:20

Sulfur Assimilation

Sulfur is an essential element in biological systems, contributing to synthesizing key biomolecules, including amino acids such as cysteine and methionine, and cofactors such as coenzyme A and biotin. Microorganisms primarily assimilate sulfur as sulfate (SO₄²⁻) from the environment, which must undergo a series of biochemical transformations before it can be incorporated into cellular components. As sulfate is highly oxidized, it must undergo assimilatory sulfate reduction to...
547
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
665
Antihypertensive Drugs: Vasodilators01:23

Antihypertensive Drugs: Vasodilators

Vasodilators, primarily affecting the smooth muscles within arterial and venous walls, are commonly used for hypertension treatment. Medications such as minoxidil and hydralazine primarily target arteries and arterioles, while sodium nitroprusside acts on arterioles and venules. Minoxidil, functioning as a prodrug, is metabolized by hepatic sulfotransferase into its active form, minoxidil sulfate, after oral administration. This metabolite binds to the sulfonylurea receptor (SUR) component of...
2.5K
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.6K